NATCO Pharma receives FDA Establishment Inspection Report for Visakhapatnam plant
NATCO Pharma announced receiving an Establishment Inspection Report from the US FDA for its FDF Unit. The inspection took place in Vishakhapatnam from August 17 to August 21. The company noted that the FDA issued four observations in the Form-483 ...
According to the company’s press release, the FDA conducted an inspection at the FDF manufacturing plant located in Parawada, Visakhapatnam, from August 17 to August 21.
The firm said that it received four observations in the Form-483 from the American drug regulator, following its inspection.
Read more: Govt proposes tighter scrutiny of antimicrobial drugs to address resistance worries
The company also stated that it received EIR from the U.S. FDA on the classification of the above referred inspection as Voluntary Action Indicated (VAI).
A Form-483 lists objectionable conditions observed during an inspection, while a VAI classification means the company is expected to address them voluntarily without USFDA regulatory action, according to PTI.
NATCO Pharma Limited develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products, the release said.
Following the announcement, NATCO Pharma's share price on the Bombay Stock Exchange has fallen by 0.35% to ₹818.65, as of 02:32, November 20.
(With inputs from PTI)
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.